Clinical Trials Arena on MSN13d
Bambusa Therapeutics doses first volunteers in Phase I bispecific AD trial
The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...
Hosted on MSN25d
Bispecific antibody startup Bambusa raises $90m to fund clinical trials
US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory disorders into the clinic.
BioWorld25d
Series A financing at Bambusa to advance bispecific antibodies for immunological and inflammatory disorders
Bambusa Therapeutics Inc. has completed an oversubscribed series A financing of approximately $90 million to support its lead programs through phase I trials and advance its pipeline of long-acting ...
FierceBiotech28d
Boston biotech Bambusa banks $90M for next-gen bispecifics
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions. New investor RA Capital ...